OTEZLA (apremilast), PDE4 inhibitor immunosuppressant
DERMATOLOGY - New medicinal product
Opinions on drugs - Posted on Apr 15 2016
Reason for request
- OTEZLA (oral) has a Marketing Authorisation in the treatment of moderate to severe chronic plaque psoriasis in adult patients in case of failure, contraindication or intolerance to other systemic treatments including ciclosporin, methotrexate or PUVA therapy.
- Its modest efficacy has been demonstrated compared with placebo in patients refractory to topical treatments. No clinical benefit has been demonstrated compared with other conventional or biological systemic treatments.
- It is a second-line systemic treatment, after failure of other non-biological systemic treatments. It can be useful for delaying the start of treatment with biotherapy.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments